Dawaon ke daam par Supreme Court ke sawaal jaayaz hain — ab Centre ko thos jawab dena hoga

Mangalvaar ko Supreme Court ki Justice Vikram Nath aur Justice Sandeep Mehta ki bench ne dawaon ki keemat par jo tippaniyan kin, woh kisi bhi sarkar ke liye asahaj hain. ANI ki report ke mutabik bench ne poocha ki poora system manufacturers ki madad karta kyun dikhta hai, National Pharmaceutical Pricing Authority ko 'totally defunct' kaha, aur ek commercial hospital mein dawaon par 100 se 200 guna markup par sawaal uthaya. Yachika mein daava hai ki lagbhag 82% dawaen DPCO, 2013 ki scheduled list se baahar hain, yaani unki shuruaati keemat par seedha niyantran nahi hota.

Centre ki taraf se Additional Solicitor General Aishwarya Bhati ne kaha ki India mein dawaon ki keemat duniya mein sabse kam mein se hai, aur sarkar policy ki lagataar samiksha karti hai. Yeh daava apni jagah sahi ho sakta hai — India generic dawaon ka bada supplier hai. Lekin bench ka jawab bhi utna hi wazandaar tha: sasti ya mehngi ka paimana desh ki kam per capita income se tay hona chahiye, na ki doosre deshon se tulna se.

Hamari raay mein asli mudda keemat ka nahi, kami-beshi ka hai. Jab ek hi cheez thok mein kuch rupaye ki aur mareez ke bill mein kai guna mehngi ho, toh sawaal regulation ki dhaar par uthta hai. Hospitals ki daleel — 24 ghante ka infrastructure, nakli dawaon se bachav, operational kharch — sunne layak hai, par isse dawaon par behisaab margin ko jaayaz nahi thehraya ja sakta. Iska saaf hal hai: kharch ka hisaab alag dikhe, aur dawa ka markup ek tay seema mein rahe.

Bench ne order surakshit rakh liya hai. Faisla jo bhi ho, Centre ko court ke intezaar ke bina hi trade margin rationalisation ko tez karna chahiye, NPPA ko zaroori sansadhan aur adhikaar dene chahiye, aur generic prescription ko badhava dena chahiye. Ilaaj ka kharch aaj bhi kai parivaron ko karz mein dhakelta hai; dawa ka bill us bojh ka sabse bada hissa na bane, yeh sunishchit karna sarkar ki zimmedari hai.